AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

IMUGENE LTD

0.215

-0.025-10.42%

Volume:2.63M

Turnover:591.97K

Market Cap:69.13M

PE:-0.93

High:0.242

Open:0.240

Low:0.207

Close:0.240

52wk High:1.394

52wk Low:0.207

Shares:321.52M

Float Shares:254.20M

Volume Ratio:4.93

T/O Rate:1.03%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.230

EPS(LYR):-0.316

ROE:-111.29%

ROA:-39.22%

PB:1.65

PE(LYR):-0.68

Loading ...

Overview Company News Filings

Company Profile

Company Name:

IMUGENE LTD

Exchange:

ASX

Establishment Date:

- -

Employees:

15

Office Location:

4-6 Bligh Street,Suite 12.01, Level 12,Sydney,New South Wales,Australia

Website:

http://www.imugene.com

Zip Code:

2000

Phone:

Fax:

61 2 9423 0881

Introduction:

Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia. Its lead product is HER-Vaxx, a HER2-positive cancer vaccine that stimulates a polyclonal antibody response against HER2/neu receptors in gastric and breast cancer. The company's HER-Vaxx is in Phase 1b/2 study for gastric cancer. It also engages in developing PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling; and B-Vaxx, a cancer vaccine to treat tumors that over-express the HER2/neu receptor. Imugene Limited was incorporated in 1986 and is headquartered in Sydney, Australia.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/IMU.AU/company"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"IMU.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"IMU.AU\",,,,,undefined,":{"symbol":"IMU.AU","market":"AU","secType":"STK","nameCN":"IMUGENE LTD","latestPrice":0.215,"timestamp":1772423292658,"preClose":0.24,"halted":0,"volume":2629885,"delay":0,"changeRate":-0.10416666666666664,"nameEN":"IMUGENE LTD","floatShares":254199099,"shares":321515615,"eps":-0.230051,"marketStatus":"Trading","change":-0.025,"latestTime":"03-02 14:49:22 AEDT","open":0.24,"high":0.242,"low":0.207,"amount":591971,"amplitude":0.145833,"askPrice":0.22,"askSize":167021,"bidPrice":0.21,"bidSize":159076,"shortable":3,"etf":0,"ttmEps":-0.230051,"tradingStatus":2,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1772427600000},"marketStatusCode":2,"adr":0,"exchange":"ASX","adjPreClose":0.24,"openAndCloseTimeList":[[1772406000000,1772427600000]],"volumeRatio":4.932503,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"IMU.AU\",,,,,undefined,":{"symbol":"IMU.AU","floatShares":254199099,"roa":"-39.22%","roe":"-111.29%","lyrEps":-0.315594,"volumeRatio":4.932503,"shares":321515615,"dividePrice":0,"high":0.242,"amplitude":0.145833,"preClose":0.24,"low":0.207,"week52Low":0.207,"pbRate":"1.65","psRate":"17.53","week52High":1.394,"institutionHeld":0,"latestPrice":0.215,"committee":-0.024364,"eps":-0.230051,"divideRate":0,"volume":2629885,"delay":0,"ttmEps":-0.230051,"open":0.24,"prevYearClose":0.365,"prevWeekClose":0.24,"prevMonthClose":0.24,"prevQuarterClose":0.365,"fiveDayClose":0.25,"twentyDayClose":0.27,"sixtyDayClose":0.33},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IMU.AU\",params:#limit:5,,,undefined,":[{"market":"AU","date":"2025-07-02","symbol":"IMU.AU","type":"split","dateTimestamp":1751378400000,"forFactor":34,"toFactor":1,"ratio":34}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IMU.AU\",market:\"AU\",,,undefined,":[],"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{"companyId":11113368,"employeeNum":15,"address":"4-6 Bligh Street,Suite 12.01, Level 12,Sydney,New South Wales,Australia","zipCode":"2000","officePhone":"61 2 9423 0881","officeFax":"61 2 9423 0881"},"stockCompanyDetail":{"websiteUrl":"http://www.imugene.com","stockEarnings":[{"period":"1week","weight":-0.04},{"period":"1month","weight":-0.25},{"period":"3month","weight":-0.3043},{"period":"6month","weight":-0.1579},{"period":"1year","weight":-0.8142},{"period":"ytd","weight":-0.3425}],"compareEarnings":[{"period":"1week","weight":0.0138},{"period":"1month","weight":0.0259},{"period":"3month","weight":0.0551},{"period":"6month","weight":0.0911},{"period":"1year","weight":0.2078},{"period":"ytd","weight":0.0355}],"compareStock":{"symbol":"F100.AU","name":"BETASHARES FTSE 100 ETF"},"description":"Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia. Its lead product is HER-Vaxx, a HER2-positive cancer vaccine that stimulates a polyclonal antibody response against HER2/neu receptors in gastric and breast cancer. The company's HER-Vaxx is in Phase 1b/2 study for gastric cancer. It also engages in developing PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling; and B-Vaxx, a cancer vaccine to treat tumors that over-express the HER2/neu receptor. Imugene Limited was incorporated in 1986 and is headquartered in Sydney, Australia.","yearOnYearQuotes":[{"month":1,"riseRate":0.375,"avgChangeRate":-0.034991},{"month":2,"riseRate":0.304348,"avgChangeRate":-0.027606},{"month":3,"riseRate":0.434783,"avgChangeRate":0.036578},{"month":4,"riseRate":0.26087,"avgChangeRate":-0.015421},{"month":5,"riseRate":0.130435,"avgChangeRate":-0.107109},{"month":6,"riseRate":0.652174,"avgChangeRate":0.189039},{"month":7,"riseRate":0.521739,"avgChangeRate":0.046722},{"month":8,"riseRate":0.347826,"avgChangeRate":-0.014697},{"month":9,"riseRate":0.458333,"avgChangeRate":0.044309},{"month":10,"riseRate":0.541667,"avgChangeRate":0.1478},{"month":11,"riseRate":0.291667,"avgChangeRate":0.035512},{"month":12,"riseRate":0.25,"avgChangeRate":-0.058143}],"exchange":"ASX","name":"IMUGENE LTD","nameEN":"IMUGENE LTD"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"IMU.AU\",market:\"AU\",,,undefined,":null}}